MABTHERA TRIAL SHOWS POSITIVE RESULTS

Roche has announced that a Phase III trial of cancer treatment MabThera in lymphoma has shown positive results earlier than expected. MabThera, which is currently on trial by the European Organization for Research and Treatment of Cancer as a treatment in relapsed indolent non-Hodgkin's lymphoma (NHL), is administered over two years and aims to prevent disease recurrence.

NHL affects 1.5 million people worldwide. Indolent NHL, affecting about 45 percent of all NHL patients, is a slow-developing but serious cancer of the lymphatic system.